Physiomics PLC Completion of Innovate UK Grant Project
12 March 2018 - 6:00PM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
12 March 2018
12(th) March 2018
Physiomics plc
("Physiomics") or ("the Company")
Completion of Innovate UK Grant Project on Personalised
Treatment of Oesophageal Cancer
Physiomics plc (AIM: PYC), a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry, is pleased to confirm that is has
successfully completed the Innovate UK grant project announced in
January 2017. The project was formally signed off by Innovate UK
following a final project meeting in February this year. The
Company can confirm that, in line with expectations, it received
total funding of GBP131k from Innovate UK over the course of the
project, of which around GBP81k will be recognised in the Company's
current financial year.
The project "Decision Support System For Stratified Cancer
Treatment" analysed data from over 400 oesophageal cancer patients
to determine patient and disease specific factors that could help
guide treatment to achieve the best outcomes, and created a tool
for healthcare professionals to visualise this data. The project
was conducted in collaboration with Prof Mark Middleton of Oxford
University and the Oxford AHSN, and the Company intends to
publicise the key results and findings of the project through an
abstract, poster and other publications over the course of 2018
(further announcements will be forthcoming).
The results and learnings from the project have potential
applications in both the Company's existing business advising
R&D based pharmaceutical and biotech companies as well as in
the emerging field of personalised cancer treatment. In order to
further develop the technology the company is actively seeking
additional grants in this space (as originally announced in October
2017).
The Company believes that the field of personalised or
stratified cancer treatment, whether in R&D or in clinical
practice will continue to gain importance in the short to medium
term and that the Company is well positioned to contribute towards
its development.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell/James Sinclair-Ford
+44 (0) 113 394 66 00
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
About Physiomics plc
Physiomics plc (AIM: PYC) is a solutions provider to the
R&D-based pharmaceutical and biotechnology industry with a
focus on oncology. The Company's Virtual Tumour technology uses
computer modelling to predict the effects of cancer drugs and
treatments to improve the success rate of drug discovery and
development projects while reducing time and cost. The predictive
capability of Virtual Tumour has been confirmed by 55 projects,
involving over 25 targets and 60 drugs.
Based in Oxford, UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics' senior management has academic and commercial
expertise, including over 90 years collectively of working in
oncology and/or computational biology and over 100 publications in
peer reviewed journals.
About Innovate UK
Innovate UK is the UK's innovation-agency. It works with people,
companies and partner organisations to find and drive the science
and technology innovations that will grow the UK economy. For
further information visit www.innovateuk.gov.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSWFMUFASEFD
(END) Dow Jones Newswires
March 12, 2018 03:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024